Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obe-cel in Refractory Progressive Multiple Sclerosis
NCT07139743Phase 1Recruiting
- Sponsor
- Autolus Therapeutics plc
- Start
- Aug 2025
- Primary completion
- Aug 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of obecabtagene autoleucel in progressive multiple sclerosis (PMS), sponsored by Autolus Therapeutics plc. Primary endpoints: Dose-Limiting Toxicities at 4 weeks and Safety and Tolerability at 24 months. Started Aug 2025; status: recruiting.
02
Drugs
obecabtagene autoleucel
03
Conditions
progressive multiple sclerosis (PMS)
Beyond the preview
Go deeper on NCT07139743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07139743.